Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose Design 9 System

Inclusion Criteria: * patient/legal representative provides written informed consent * Patient is scheduled for a coronary or peripheral diagnostic or interventional procedure * Target vessel has a lumen diameter ≥ 6 mm * Patient must be willing to comply with follow-up requirements * Patient has a 5-7F arterial puncture located in the common femoral artery Exclusion Criteria: * Arterial puncture in the femoral artery of both legs * Manual compression has been preformed on the ipsilateral arterial site within the previous 6 weeks * Any closure system has been used on the ipsilateral arterial site within the previous 180 days * Any reentry of the ipsilateral site is planned within the next 6 weeks * History of surgical repair of blood vessels of the ipsilateral arterial site * Patient is unable to ambulate at baseline * Significant bleeding diathesis or platelet dysfunction 1. Thrombocytopenia (Plt count ≤ 100,000) 2. Anemia (Hgb ≤ 10mg/dl and/or Hct ≤ 30mg/dl) 3. Hemophilia 4. Von Willebrand"s disease 5. Thrombophilia (i.e. factor 5 deficiency or other) * ST-elevation myocardial infarction ≤ 48 hours prior to the cardiac or peripheral catheterization procedure * Pre-existing severe non-cardiac systemic disease or pre-existing terminal illness * Pre-existing systemic or cutaneous infection * Receiving warfarin therapy within the last 14 days. * INR results \> 1.2 on day of procedure for any patient with a history of warfarin therapy * Thrombolytic therapy (e.g. streptokinase, urokinase, t-PA) ≤ 24 hours prior to the cardiac or peripheral catheterization procedure * Concurrent participation in another investigational device or drug trial * Angiomax (bivalirudin) or other thrombin-specific anticoagulants or low molecular weight heparin ≤ 24 hours prior to the cardiac or peripheral catheterization procedure * Planned arterial access at the same access site ≤ 30 days following the femoral artery closure procedure * Evidence of a preexisting hematoma, arteriovenous fistula, or pseudoaneurysm at the access site prior to start of femoral artery closure procedure * Prior femoral vascular surgery or vascular graft in region of access site or contralateral common femoral artery * Symptomatic leg ischemia in the target vessel limb including severe claudication or weak/absent pulse * Absent of pedal pulse on ipsilateral side * Pre-existing autoimmune disease * BMI \> 40 kg/m2 * The targeted femoral artery is tortuous or requires an introducer sheath length \> 11 cm * Fluoroscopically visible calcium, atherosclerotic disease, or stent ≤ 1 cm of the puncture site that would interfere with the placement of the VCD's plug * Suspected bacterial contamination of access site * Puncture through a vascular graft * Double wall puncture * Antegrade puncture * Palpable Hematoma * Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture * Any Arterial and/or Venous access on the ipsilateral or contralateral groin other than target study access site * Patient is not cooperative * Intra-procedural therapeutic thrombolysis is preformed * Uncontrolled hypertension at time of sheath removal (blood pressure ≥ 170 mmHg systolic and/or ≥ 100mmHg diastolic) * Peripheral vascular disease on the ipsilateral arterial vessel (≥ 50% stenosis) or aneurismal disease of this vessel. * Sheaths has been changed during the procedure * Heparinized patients with elevated pre-closure ACT level≥ 300 seconds * Patient has known allergy to any materials used in the VCD * Patient is known to require an extended hospitalization (e.g. patient is undergoing CABG surgery) * Prior or recent use of an intra-aortic balloon pump through the arterial access site * Cardiogenic shock (hemodynamic instability requiring intravenous medications or mechanical support) experienced during or immediately post-catheterization * Patient is known or suspected to be pregnant, or is lactating * Patient has known allergy to contrast medium * Any angiographic or clinical evidence that the investigator feels would place the patient at increased risk with the use of the VCD * Required simultaneous ipsilateral or contralateral venous puncture